 Kazia Therapeutics Ltd ASX:KZA NASDAQ:KZIA FRA:NV9 made substantial progress and achieved key milestones in the half-year ending December 31, 2020, ending the period with a cash balance of A19.4 million and net assets of A31.7 million. Chairman Iain Ross stated in the half-year report that in line with Kazias ongoing focus on cost efficiency, more than 90 of its expenditure in this period was invested directly in RD programs. 